GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (MEX:JNJ) » Definitions » Institutional Ownership

Johnson & Johnson (MEX:JNJ) Institutional Ownership : 43.83% (As of Apr. 01, 2025)


View and export this data going back to 1990. Start your Free Trial

What is Johnson & Johnson Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Johnson & Johnson's institutional ownership is 43.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Johnson & Johnson's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Johnson & Johnson's Float Percentage Of Total Shares Outstanding is 99.96%.


Johnson & Johnson Institutional Ownership Historical Data

The historical data trend for Johnson & Johnson's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Institutional Ownership Chart

Johnson & Johnson Historical Data

The historical data trend for Johnson & Johnson can be seen below:

2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28
Institutional Ownership 41.71 41.67 43.00 43.30 43.70 43.92 43.79 43.62 43.66 43.83

Johnson & Johnson Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Johnson & Johnson Business Description

Address
One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.